Vitrafy Life Sciences (VFY) H1 2026 earnings summary

Executive summary

• Achieved a major commercial milestone with a 12-month exclusive agreement with IMV Technologies for animal health, providing immediate and milestone-based revenue and market validation.

• Expanded U.S. operations with new hires, a California office, and the launch of the Guardion device, supporting sales, demos, and market entry.

• Completed Phase 1 blood platelet trials with the U.S. Military, generating strong commercial interest for civilian applications and progressing human health initiatives.

• Built out U.S. manufacturing and supply chain capabilities, including partnerships to support device deployment and cost efficiencies.

• No significant changes in the state of affairs or material commitments during the period.

Financial highlights

• Revenue and other income for the half-year totaled $1,984,410, mainly from grants and incentives, with sales revenue of $8,868.

• Net loss after tax was $7,124,467, a significant improvement from $25,683,508 in the prior period.

• Cash and liquid assets totaled $22.8 million at 31 December 2025, including $10.1 million in term deposits.

• Confident cash runway forecasted through calendar year 2027, even with increased spend on manufacturing and U.S. expansion.

• Immediate revenue from IMV contract expected to be up to $0.9 million over 12 months, plus milestone payments.

Outlook and guidance

• Anticipates near-term readouts from Phase II U.S. Army studies, which are critical for commercial agreements and FDA registration.

• Focused on expanding and converting customer pipeline opportunities in human health and animal reproduction, especially in the U.S.

• Plans to ramp up device manufacturing and secure FDA Class II medical device clearance to expand addressable markets.

• Expects further value creation from FDA registration, commercial scaling, and new market entries.

• Continued focus on customer onboarding, education, and success programs to drive recurring revenue.